Danya Ben-Hail
JonesTrading Institutional Services, LLC, Research Division

Hello, everyone. Welcome to Jones fireside chat with Dr. Eran Ophir, President and CEO of Compugen. I am Danya Ben Hail, an analyst at Jones Research.

Compugen was doing computational target discovery long before AI and biotech became a buzzword. Today, we'll explore what it really takes to turn predictive biology into first-in-class immuno-oncology drugs. Eran, thank you for joining us.

Eran Ophir
CEO, President & Director

Thank you Danya for inviting.

Danya Ben-Hail
JonesTrading Institutional Services, LLC, Research Division

Let's start with the foundation. Compugen repeatedly uncovers first-in-class targets where our traditional discovery methods stall. Every AI company today claims a data advantage. Getting started, can you give a brief overview on Compugen's platform and what makes it unique?

Eran Ophir
CEO, President & Director

So first, as you mentioned, we are not just a recent AI story that's saying that we're doing AI, just to have the buzzword in the name of the company. We're doing it a long time ago. We have built the system. We have this engine called Unigen. And so this is one.

I think the second part is the stage of the research and development that we are focused in, which is relatively unique. I mean you gathered a really nice group of companies in this set of fireside chat with AI companies. Most of them are doing, for example, AI to identify the drug targets, to identify easier, maybe better antibodies, small molecules. But we are focusing on the very first stage of the research and development on the drug target itself, which target, which